WO2018146575A1 - Rapid-release composition of cinitapride and simeticone and method for preparing same - Google Patents
Rapid-release composition of cinitapride and simeticone and method for preparing same Download PDFInfo
- Publication number
- WO2018146575A1 WO2018146575A1 PCT/IB2018/050528 IB2018050528W WO2018146575A1 WO 2018146575 A1 WO2018146575 A1 WO 2018146575A1 IB 2018050528 W IB2018050528 W IB 2018050528W WO 2018146575 A1 WO2018146575 A1 WO 2018146575A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cinitapride
- propylene glycol
- simethicone
- composition according
- composition
- Prior art date
Links
- 0 *C(C[C@](*=N)C(*)=CCI(I*(C(CC1)CC*1I(C1CC#CCC1)#C)=C)=O)=C Chemical compound *C(C[C@](*=N)C(*)=CCI(I*(C(CC1)CC*1I(C1CC#CCC1)#C)=C)=O)=C 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Definitions
- the present invention relates to a pharmaceutical composition for oral administration, in the form of capsules with liquid content, of rapid release, comprising a fixed-dose combination of Cinitapride tartrate and Simethicone together with at least one surfactant and optionally one or more pharmaceutically acceptable excipients, and the process for obtaining said composition.
- Cinitapride was revealed as active ingredient in the German patent application DE 2,751,139 and its equivalents, the applicant was ANPHAR SA and claimed as a priority the English application with serial number No. 47739 of November 16, 1976 According to the IUPAC nomenclature the compound Cinitapride is known under the name 4-amino-N- [1- (3-cyclohexen-1-ylmethyl) -4-piperidinyl] -2-ethoxy-5-nitrobenzamide, and is represented by the following Formula (I):
- This compound is an orthopramide with prokinetic activity at the level of the gastrointestinal tract that possesses a marked pro-cholinergic action.
- By blocking the presynaptic receptors for serotonin the release of serotonin increases, resulting in increased serotonergic activity. Its discrete antidopaminergic activity contributes to the therapeutic effect.
- Cinitapride has been shown to antagonize gastroparesis and vomiting induced by L-dopa.
- Cinitapride significantly accelerated the gastric evacuation time in patients with pathological delay of gastric emptying. Cinitapride improves the clinical symptomatology of patients with dyspepsia associated with slowing of gastric emptying and delay of gastrointestinal transit.
- the absorption of Cinitapride, after oral administration, is rapid and reaches the maximum plasma concentration at 2 hours. It is metabolized at the hepatic level (> 90%) with an important hepatic first pass metabolism. No accumulation has been observed after repeated administration of Cinitapride. This compound is indicated in the treatment of dyspepsia of mild to moderate dysmotility in a dose of up to 3 mg per day.
- the compound Simethicone is a mixture of Dimethicone with silicon dioxide. Its IUPAC nomenclature is a- (trimethylsilyl) - ⁇ -methylpoly [oxy (dimethylsilylene)], mixed with silicon dioxide, and is represented by Formula (II)
- Simethicone is a chemically inert compound that is not absorbed in the gastrointestinal tract. It is excreted as it was ingested, in the stool and without evidence of hepatic whole circulation. Simethicone alters the surface tension of gas bubbles that form in the gastrointestinal tract, either in the digestive process itself or due to lactose intolerance. Its action allows the gas bubbles to break and form much smaller ones that are easily eliminated both orally and rectally. The clinical use of Simethicone is based on its anti-foam property demonstrated in vitro. This compound is indicated in the treatment of functional gastrointestinal conditions in which gas retention can be a problem.
- U.S. Patent No. 4,582,709 whose headline was Warner Lambert, with a US priority date of February 8, 1985, claimed a chewable mineral supplement and process to obtain it.
- Said product comprises from about 3 to about 40% by weight of mineral compound, and from about 1.5 to about 6% by weight of an edible polyalcohol mixed with a sweet caramel base,
- Bl whose title is Advanced Technology Pharmaceuticals Corp, and with a US priority date of December 12, 1991, claims a dry, antifoam granular composition comprising a water-soluble agglomerate, based on carbohydrates and a non-aqueous liquid selected from hydrocarbon oils. and silicone oils.
- the Carbohydrates were selected from maltodext quarrel, dextrose, sucrose, fructose, mannitol and agglomerates of sorbitol.
- European patent with publication number EP 1 297 825 Bl whose title is McNeil-PPC, INC and with US priority No. 09 / 966,441 dated September 28, 2001, claims a composition for producing a compressed solid dosage form comprising Simethicone, a mixture of silicified microcrystalline cellulose and magnesium aluminometasilicate as an adsorbent, and an optional active agent.
- Simethicone is adsorbed in an inert material that can be, microcrystalline cellulose, calcium phosphate, pregelatinized corn starch, colloidal silica, hydroxypropylcellulose, magnesium oxide and magnesium hydroxide, in the form of a chewable tablet. It includes combinations with one or more antacids, antidiarrheals, antispasmodics, laxatives, antiemetics and anticholinergics.
- the subject of the present invention relates to a pharmaceutical composition for oral administration, in the form of liquid-containing capsules, comprising a fixed-dose combination of Cinitapride tartrate and Simethicone together with at least one surfactant and optionally one or more excipients pharmaceutically acceptable.
- the composition is designed so that Cinitapride and Simethicone are released quickly after the disintegration of the capsule in the gastrointestinal tract.
- This composition was designed to treat gastrointestinal disorders, especially dyspepsia.
- the patients to whom this kind of composition is indicated not only suffer from dyspepsia, but also tend to have other symptoms such as gastroesophageal reflux, gastritis, high gastric acidity generating irritation of the esophageal mucosa, this condition can lead to a dysphagia (difficulty in swallowing) and / or dinophagia (pain during swallowing).
- a formulation containing the two active ingredients, Cinitapride and Simethicone was designed in therapeutically effective doses, where Cinitapride was incorporated micronized to Simethicone, immediately finding the drawback of the lack of homogeneity of the composition since Cinitaprida tends to agglomerate after being incorporated in the Simethicone, leaving a fraction of Cinitaprida floating on the surface of Simethicone, without being integrated into the formulation.
- Cinitapride has a granulometry d (90) of approximately 100 microns a good dispersion is not formed, therefore, it must be ground. It was found that the optimal value is 50 microns or less.
- Cinitapride suspended in Simeticona liquida allows its simultaneous administration in a capsule of small volume and easy swallowing.
- the invention relates to a pharmaceutical composition for oral administration, of rapid release, comprising a fixed-dose combination of Cinitapride tartrate and Simethicone, with Cinitapride ground and suspended in Simethicone together with at least a surfactant agent, and encapsulated in hard capsules with liquid content or in soft capsules.
- This composition is designed for the treatment of functional gastrointestinal disorders, especially dyspepsia.
- Cinitapride Therapeutically effective doses of Cinitapride are in the range of 1 to 3 mg, according to Martindale, Cinitapride, The Complete Drug Reference, Volume 1, Edition 36, 2009, 1720.
- the therapeutically effective doses of Simethicone are comprised in the range of 20 to 1000 mg, according to Martindale, Simeticona, The complete drug reference, Volume A, edition 38, 2014, 1886: 1887.
- the invention relates to the process for obtaining the composition, which includes milling the Cinitapride to a size of d (90) of 50 microns or less, incorporating it into the vehicle (liquid surfactant agent), mixing with the Simethicone and finally encapsulate.
- the process for preparing a composition comprising a combination of Cinitapride, suspended in Simethicone by the use of medium chain Triglycerides as liquid carrier is described.
- the test batch is 100 g.
- step 2 Add Simethicone to the dispersion from step 1 and heat to a temperature of approximately 35 2 C while maintaining constant agitation.
- Cinitapride using a ground pulverizer Once the active ingredient is ground, a particle size (d90) of 47 microns is recorded.
- Dissolution medium 0.01 N solution of hydrochloric acid.
- the excipients Capryol 90, Lauroglycol 90 and Capmul PG-2L are propylene glycol esters with medium chain fatty acids and have a surfactant action.
- Cinitapride titration 1.03 mg per capsule.
- Simethicone rating 208 mg per capsule.
- Cinitapride solution 94.9% (compliant)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019015989-4A BR112019015989A2 (en) | 2017-02-07 | 2018-01-29 | COMPOSITION OF QUICK RELEASE OF CINITAPRIDE AND SIMETICONE AND PROCESS TO PREPARE THE SAME |
CR20190402A CR20190402A (en) | 2017-02-07 | 2018-01-29 | Rapid-release composition of cinitapride and simeticone and method for preparing same |
PE2019001412A PE20191491A1 (en) | 2017-02-07 | 2018-01-29 | QUICK RELEASE COMPOSITION OF CINITAPRIDE AND SYMETICONE AND PROCESS TO PREPARE IT |
CONC2019/0008347A CO2019008347A2 (en) | 2017-02-07 | 2019-07-30 | Quick release composition of cinitapride and simethicone and process to prepare it |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017001714A MX2017001714A (en) | 2017-02-07 | 2017-02-07 | Rapid-release composition of cinitapride and simeticone and method for preparing same. |
MXMX/A/2017/001714 | 2017-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018146575A1 true WO2018146575A1 (en) | 2018-08-16 |
Family
ID=63108046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/050528 WO2018146575A1 (en) | 2017-02-07 | 2018-01-29 | Rapid-release composition of cinitapride and simeticone and method for preparing same |
Country Status (10)
Country | Link |
---|---|
AR (1) | AR110797A1 (en) |
BR (1) | BR112019015989A2 (en) |
CL (1) | CL2019001944A1 (en) |
CO (1) | CO2019008347A2 (en) |
CR (1) | CR20190402A (en) |
DO (1) | DOP2019000190A (en) |
EC (1) | ECSP19051198A (en) |
MX (1) | MX2017001714A (en) |
PE (1) | PE20191491A1 (en) |
WO (1) | WO2018146575A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6676933B2 (en) * | 2001-05-23 | 2004-01-13 | Osmotica Corp. | Pharmaceutical composition containing mosapride and pancreatin |
WO2004071374A2 (en) * | 2003-02-11 | 2004-08-26 | Torrent Pharmaceuticals Limited | Once a day orally administered pharmaceutical compositions |
US20070298099A1 (en) * | 2004-11-24 | 2007-12-27 | Peresypkin Andrey V | Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide |
WO2009066146A2 (en) * | 2007-11-19 | 2009-05-28 | Cadila Pharmaceuticals Ltd. | Stable solutions of sparingly soluble actives |
-
2017
- 2017-02-07 MX MX2017001714A patent/MX2017001714A/en unknown
-
2018
- 2018-01-29 BR BR112019015989-4A patent/BR112019015989A2/en active Search and Examination
- 2018-01-29 CR CR20190402A patent/CR20190402A/en unknown
- 2018-01-29 WO PCT/IB2018/050528 patent/WO2018146575A1/en active Application Filing
- 2018-01-29 PE PE2019001412A patent/PE20191491A1/en unknown
- 2018-02-06 AR ARP180100282A patent/AR110797A1/en unknown
-
2019
- 2019-07-11 CL CL2019001944A patent/CL2019001944A1/en unknown
- 2019-07-16 EC ECSENADI201951198A patent/ECSP19051198A/en unknown
- 2019-07-19 DO DO2019000190A patent/DOP2019000190A/en unknown
- 2019-07-30 CO CONC2019/0008347A patent/CO2019008347A2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6676933B2 (en) * | 2001-05-23 | 2004-01-13 | Osmotica Corp. | Pharmaceutical composition containing mosapride and pancreatin |
WO2004071374A2 (en) * | 2003-02-11 | 2004-08-26 | Torrent Pharmaceuticals Limited | Once a day orally administered pharmaceutical compositions |
US20070298099A1 (en) * | 2004-11-24 | 2007-12-27 | Peresypkin Andrey V | Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide |
WO2009066146A2 (en) * | 2007-11-19 | 2009-05-28 | Cadila Pharmaceuticals Ltd. | Stable solutions of sparingly soluble actives |
Non-Patent Citations (2)
Title |
---|
ROGASTRIL PLUS MASTICABLE, 29 June 2015 (2015-06-29), Retrieved from the Internet <URL:https://web.archive.org/web/20150629172859/bttps://www.roemmers.com.ar/es/productos/rogastril-plus> [retrieved on 20180411] * |
ROGASTRIL PLUS, 29 June 2015 (2015-06-29), Retrieved from the Internet <URL:hEtps://web.archive.org/web/20150629172859/btEps://wvsw.n)eaimers.coin.ar/es/productos/roeastrll-plus> [retrieved on 20180411] * |
Also Published As
Publication number | Publication date |
---|---|
PE20191491A1 (en) | 2019-10-21 |
CO2019008347A2 (en) | 2019-08-30 |
CR20190402A (en) | 2019-09-20 |
BR112019015989A2 (en) | 2020-03-31 |
ECSP19051198A (en) | 2019-07-31 |
MX2017001714A (en) | 2018-08-06 |
DOP2019000190A (en) | 2019-10-15 |
CL2019001944A1 (en) | 2019-12-06 |
AR110797A1 (en) | 2019-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2863500T3 (en) | Abiraterone Acetate Lipid Formulations | |
ES2892029T3 (en) | Enzalutamide formulations | |
ES2627531T5 (en) | Pharmaceutical composition with improved bioavailability for a high-melting hydrophobic compound | |
ES2341510T3 (en) | MICROEMULSIONS AS SOLID PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION. | |
TWI490216B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
ES2563735T3 (en) | Pharmaceutical dosage form comprising 6'-fluor- (N-methyl- or N, N-dimethyl-) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'- pyrano [3,4, b] indole] -4-amine | |
CN103153282B (en) | The pharmaceutical dosage form of ', 9 '-dihydro-3 ' H-spiral shell [cyclohexane extraction-1,1 '-pyrans is [3,4, B] indole also]-4-amine containing 6 '-fluoro-(N-methyl-or N, N-dimethyl-)-4-phenyl-4 | |
ES2451540T3 (en) | Oral dosage forms of bendamustine | |
ES2668203T3 (en) | Fexofenadine microcapsules and compositions containing them | |
ES2717282T3 (en) | Formulations and methods for manufacturing formulations for use in colonic evacuation | |
Singh et al. | Fast dissolving drug delivery systems: formulation, preparation techniques and evaluation | |
ES2253354T3 (en) | NEW SUPPLY SYSTEM OF A SELF-EMULSIONING MEDICINAL PRODUCT. | |
ES2690257T3 (en) | Oral dosage forms of bendamustine | |
ES2301455T3 (en) | Antacid pharmaceutical composition in powder form, pharmaceutical preparation containing it and process for its preparation | |
US20150342882A1 (en) | Methods of treatment using cadotril compositions | |
JP2013028603A (en) | Liquid dosage form of proton pump inhibitor | |
US20120213855A1 (en) | Dosage forms for weakly ionizable compounds | |
JP2020526512A (en) | New Secnidazole soft gelatin capsule formulation and its use | |
WO2018146575A1 (en) | Rapid-release composition of cinitapride and simeticone and method for preparing same | |
Karthika et al. | Formulation development and in vitro evaluation of curcumin-loaded solid selfnanoemulsifying drug delivery system for colon carcinoma | |
WO2010030667A2 (en) | Dosage forms for weakly ionizable compounds | |
ES2733113T3 (en) | Stable pharmaceutical composition of a water soluble vinorelbine salt | |
ES2763945T3 (en) | Pharmaceutical compositions incorporating drugs in low doses | |
CN103179953A (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
Patel | Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18751654 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019015989 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18751654 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112019015989 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190801 |